Thrombectomy Device for Dialysis Patients

Food and Drug Administration (FDA). The device was acquired by Datascope Corp. (Montvale, NJ, USA) from an R&D incubator company. Following a clinical beta test, Datascope plans to launch the product. The company states that an estimated 290,000 people in the United States alone require dialysis access, and more than 100,000 have implanted synthetic grafts for dialysis access. Datascope is a diversified medical device company that makes and markets a wide variety of healthcare products.

"Because Prolumen can clean grafts within minutes and comes pre-assembled and ready to use, we expect this innovative device will be well received in the market,” said Peter Hinchliffe, president of Datascop's interventional products division, which will market the device.




Related Links:
Datascope